India: Indian Patent Office's Consecutive Decision On Rejecting Tofacitinib Patent Application

Indian Patent Office (IPO) on September 3rd, 2015 denied Pfizer (Applicant) Inc's patent application on its rheumatoid arthritis drug Tofacitinib for the second time. The IPO rejected the Patent Application on the grounds of anticipation by prior claiming as well as on basis of Section 3(d) of the Patents Act (Act).


Pfizer Products, Inc. (Pfizer) filed Indian patent application 991/MUMNP/20031 entitled "Chiral Salt Resolution" in the Indian Patent Office (IPO) on October 27, 2003. The '991 application describes methods for effecting chiral salt resolution from racemic mixtures of enantiomers, particularly precursor enantiomers, for use in making pyrrolo[2,3-d]pyrimidine compounds. The pyrrolo[2,3-d]pyrimidine compounds are inhibitors of protein kinases, such as the enzyme Janus Kinase 3 (JAK3). The specification describes the enantiomer, 3-{(3R,4R)-4-Methyl-3-[methyl-(7Hpyrrolo[ 2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3- oxo-propionitrile, also known as tofacitinib. Tofacitinib, which is sold as XELJANZ®, is approved for use in the treatment of rheumatoid arthritis.

The said application is a national phase application of WO 02/096909 (PCT/IB02/01905) filed on May 29, 2002. The First Examination Report for the present invention was issued on 13th March, 2008 in which the Examiner rejected the claims due to lack of novelty based on the prior art (WO 0142246) as well on the basis of Section 3(d) of Indian Patent Act, 1970 The applicant filed a response on 27th January, 2009 with amended claims. Since there were outstanding objections related to Novelty, Section 3(d) and Section 8, the applicants were called for a hearing on January 22, 2015.

During the hearing, the Examiner raised a new objection for the first time that the claims were unpatentable under Section 3(d) of the India Patents Act 1970, as amended (Patent Act) and hence the application was rejected. Pfizer appealed and on October 31, 2014, the Intellectual Property Appellate Board (IPAB) contended that the patent office had violated the principles of natural justice thereby set aside the order and directed the IPO to reconsider the application.


On January 20, 2015, the applicant submitted copies of declarations of Dr. James D. Clark and Dr. Mark Edward Flanagan. The applicant further submitted the details of the corresponding applications mainly search and examination reports issued in other jurisdictions in order to comply with Section 8 requirements.

It is pertinent to mention that the present application 991/MUMNP/2003 has a filing date of May 29, 2002, claims a priority of May 31, 2001. D1 WO/0142246 (IN 241773) was filed on November 23, 2000, claims a priority date of December 10, 1999 and was published on June 14, 2001.

Although prior art D1 has an earlier priority and filing date than 991/MUMNP/2003, D1 was published after the priority date of present application 991/ MUMNP/2003.

With regards to Objection 1 of the hearing letter, the applicant submitted that D1 does not discloses or identify any known substance with known therapeutic efficacy for the application of Section 3(d) as D1 was published after the priority date of the present application.

With regards to the objection pertaining to section 3(d), the applicant submitted that while Section 3(d) is applicable to salts, isomers of known substance it is not applicable to the present application as the compound claimed (though an isomer) is not known to the public through prior publication. Therefore the claimed compound cannot be considered as "known substance" for the purpose of section 3(d).

On February 3, 2015, the applicant submitted an amended claim set amending claim 1 as recited below and canceling the remaining claim (claim 2).

Amended claim 1 "The compound 3-{(3R,4R)-4- Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)-amino]-piperidin-1yl}-3-oxo-propionitrile or a pharmaceutically acceptable salt thereof."


The following are the teachings of D1 (WO 0142246) as mentioned in the order by the Assistant Controller:

1. D1 discloses the inhibitors of JAK3 as agents for the treatment of variety of diseases.

2. Example 14 of D1 discloses the compound of the present claim without reference to stereo chemical configuration. However, D1 teaches that the compounds have asymmetric centers and therefore exist in different enantiomeric and diasteromeric forms. D1 further discloses the use of pyrrole [2,3-d]pyrimidine compounds as immunosuppressive agents for organ transplants, xeno transplantation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, type 1 diabetes and other indications where immunosuppression would be desirable. The said reference in the prior art includes both the E and Z configurations. The Compound of formula 1 may also exist as tautomers. Therefore the present form (3R, 4R) of the compound claimed by the applicant is also disclosed in the prior art.

3. Claim 20 of D1 discloses a compound 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d] pytimidin-4-yl)amino]-piperidin-1-yl}-3- oxo-propionitrile The subject matter of D1 was filed as national phase application(IN/ PCT/2002/00588/DEL) on 10th June 2002 which was proceeded to grant on 24/07/2010 bearing Patent. No. IN241773.The prior national phase application no IN/PCT/2002/00588/ DEL makes sense that the compound claimed in claim 20 is known to the applicant as the applicant Pfizer product Inc. is the same for both the application.

4. Specifically, the Assistant Controller referred to Section 13(1)(b) which refers to "anticipation by prior claiming" and states that "the invention is claimed in any claim of any other complete specification published on or after the date of filing of the applicant's complete specification, being a specification filed in pursuance of an application for a patent made in India and date before or claiming the priority date earlier than that date". The Assistant Controller noted that for the purpose of determining novelty, an application for a patent filed in the Indian Patent Office before the filing date of a complete specification of a later filed application but published later, is prior art for the purposes of "prior claiming".


The Assistant Controller mentioned that he did not find any distinctive difference between the instant claimed compound and the priorly claimed document D1 except the fact the former is the enantiomer of the later. Further, the Asst. Controller stated that the applicant in order to prove enhanced efficacy factor of the claimed compound has taken shelter of the document published in Journal of Medicinal Chemistry on 19th November 2008 containing all four possible enantiomer of the base compound of D1 is misleading.

D1 (WO/0142246): discloses 3-{4-Methyl-3-[methyl- (7H-pyrrolo[2,3-d] pyrimidin-4-yl)-amino]-piperidin- 1yl}-3-oxo-propionitrile.

991/MUMNP/2003 (WO/02/096909): claims the enantiomer 3-[(3R,4R)-4-methyl-3-[methyl(7Hpyrrolo[ 2,3-d] pyrimidin-4-yl) amino] piperidin-1-yl]-3- Oxopropanenitrile

The Asst. Controller stated that the Applicant has not given an experimental date to show the enhanced efficacy over the base compound.

The applicant submitted that 3-[(3R,4 R)-4-methyl-3- [methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidin-1-yl]-3-oxopropanenitrile (Tofacitinib) has 2 chiral centers at C3 and C4, with 4 possible stereoisomers. According to the applicant, among the four possible Tofacitinib enantiomers 3R, 4R/ 3R, 4S/ 3S, 4S/ 3S, 4R, only the 3R, 4R enantiomer (Tofacitinib) exhibits high level of selectivity for the Jak family kinases. The applicant explained that the stereo specific nature of the of the compound1(3R,4R) and it is selectivity against over 300 kinases resulted in improved efficacy of the compound as the binding of the molecule to the protein target is what is responsible for any drug molecule to exhibit efficacy. The applicants relied on 2008 publication by the inventors and submitted that Tofacitnib i.e. the 3R, 4R enantiomer highly selective for Janus kinase family of receptors compared to the rest of enantiomers i.e. 3S, 4S; 3R, 4S; 3S, 4R.

However, the Controller stated that as per the provisions of Section 3(d) the enantiomer of the known compound 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pytimidin- 4-yl)amino]-piperidin-1-yl}-3-oxo-propionitrile which the applicant claims should show an enhanced efficacy over the compound of the prior art. Whereas the experimental data and explanation provided during hearing submission by the Applicant showed the efficacy of the claimed compound by comparing the compound with other enantiomeric forms.

The Asst. Controller said that the applicants should have demonstrated efficacy in the patent application and should not rely on a later publication(2008) to demonstrate efficacy. "The applicant did not prove the claimed compound to be of significant efficacy and such factors were never been a part of their disclosure in the specification filed in 31st May, 2001. Rather they have taken shelter of a document of the year 2008 which is not its invention and trying to correlate their invention with the findings of the said document. The applicant is supposed to establish the enhancement of therapeutic efficacy of the specifically claimed form over D1 by substantive research data. They failed to provide such findings even after lapses of plethora of opportunities."


From the above decision it is obvious that "The enhanced efficacy criteria can be seen as a refinement of non-obviousness principles or it could be perceived as an improved utility test where only new forms that demonstrate substantially different utility than what existed before are patentable". As per the provisions of Section 3(d) the enantiomer of the known compound which the applicant claims should show an enhanced efficacy over the compound of the prior art. However, in the present invention, the experimental data and explanation provided during hearing submission by the Applicant showed the efficacy of the claimed compound by comparing the compound with other enantiomeric forms. Further, the order clearly states that for the purpose of determining novelty, an application for a patent filed in the Indian Patent Office before the filing date of a complete specification of a later filed application but published later, is prior art for the purposes of "prior claiming". However, the order is unclear on whether it is mandatory to disclose information on a prior art application while prosecuting the patent application.


1 http // ipindiaservices.goviin /decision/991-MUMNP-2003-12609/991.MUMNP.03%20REnew.pdf

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions